Instruction for use: Konyne 80

Dosage form: Lyophilizate for the preparation of a solution for infusions

Active substance: Factors of blood coagulation II, VII, IX and X in combination [Prothrombin complex]

ATX

B02BD01 Coagulation factors IX, II, VII and X in combination

Pharmacological group:

Coagulants (including factors of blood coagulation), hemostatics

The nosological classification (ICD-10)

D65-D69 Blood clotting disorders, purpura and other hemorrhagic conditions: Hyperfibrinolysis; Hypocoagulation; Increased vascular permeability; Hemorrhagic syndrome

D66 Hereditary factor VIII deficiency: Congenital insufficiency of factor VIII; Hemophilia; Hemophilia A; Hemophilia classical; Deficiency of antihemophilic factor of blood VIII; Deficiency of the coagulation factor VIII; Inhibitory form of hemophilia A; Bleeding at hemophilia A; Hereditary hemophilia; Hereditary anomalies of antihemophilic factor VIII; Failure factor VIII; Insufficiency of coagulation factor VIII; Acquired hemophilia; Coagulopathies are hereditary

D67 Hereditary factor IX deficiency: Congenital factor IX deficiency; Congenital deficiency of the coagulation factor IX; Hemorrhagic syndrome with factor IX deficiency; Hemophilia B; Hemophilia B with a factor IX inhibitor; Hemophilia B in children; Deficiency of the coagulation factor IX; Inhibitory form of hemophilia; Inhibitory form of hemophilia B; Coagulopathies are hereditary; Bleeding and haemorrhage in hemophilia B; Bleeding with acquired or congenital deficiency of factor IX; Hereditary hemophilia

D68.2 Hereditary deficiency of other coagulation factors: Coagulation factor II deficiency; Deficiency of the clotting factor VII; Deficiency of the coagulation factor X; Deficiency of the coagulation factor XII; Dysfibrinogenemia; Hereditary anomalies of the Stewart-Prower factor (factor X); Hereditary anomalies of factor Hageman (factor XII); Insufficiency of plasma clotting factors; Stuart-Prower factor deficiency; Hereditary deficiency of AT-III

R58 Bleeding, not elsewhere classified: Abdominal apoplexy; Hemorrhagia; Haemorrhage of the esophagus; Hemorrhage; Generalized bleeding; Diffuse bleeding; Diffuse bleeding; Prolonged bleeding; Blood loss; Blood loss during surgical interventions; Bleeding during surgery and in the postoperative period; Bleeding during labor; Bleeding and haemorrhage in hemophilia B; Bleeding from the gums; Bleeding intraoperative abdominal; Bleeding against a background of coumarin anticoagulants; Hepatic hepatitis; Bleeding in hemophilia A; Bleeding at hemophilia A; Bleeding with inhibitory forms of hemophilia A and B; Bleeding due to leukemia; Bleeding in patients with leukemia; Bleeding; Bleeding due to portal hypertension; Bleeding due to hyperfibrinolysis; Drug bleeding; Local bleeding; Local bleeding due to activation of fibrinolysis; Massive blood loss; Acute blood loss; Parenchymal hemorrhage; Hepatic bleeding; Postoperative hemorrhage; Kidney bleeding; Vascular-platelet hemostasis; Traumatic bleeding; Threatening bleeding; Chronic blood loss

Composition and release form

1 bottle with lyophilized powder for the preparation of the injection solution contains factor IX complex 500 or 1000 IU, as well as plasma coagulation factors II, X and an insignificant amount of factor VII (proconvertin), complete with a solvent in ampoules of 20 or 40 ml respectively, and With a two-sided needle and a needle-filter.

Pharmachologic effect

Mode action - Hemostatic.

It replenishes the deficiency of a number of factors of blood coagulation (IX, X, II, VII).

Pharmacodynamics

Increases the level of factor IX, as well as some other vitamin K-dependent factors of coagulation (II, X, VII) in blood plasma and restores hemostasis of patients with factor IX deficiency (with trauma or surgical intervention).

Indications for Konyne 80

Hemophilia B in children and adults with existing or threatening bleeding; Bleeding against a background of coumarin anticoagulants; Hemorrhage in hemophilia A in patients with factor VIII inhibitors.

Contraindications

Not.

Side effects

Feeling of heat, chills, hot flushes, tingling sensation, headache. Rarely - postoperative thrombosis.

Interaction

When used simultaneously with epsilon-aminocaproic acid, the risk of developing thrombosis increases.

Dosing and Administration

Enter only IV, maintaining a dose of 10-20 IU / kg of body weight per day. In patients with hemophilia A, the dose is 75 IU / kg; If necessary - re-introduced after 12 hours.

Precautionary measures

Do not use in people who are predisposed to thrombosis, as well as liver disease, when there is a suspicion of intravascular coagulation or fibrinolysis. With prolonged therapy, constant monitoring of the levels of factor II, IX and X in the blood of patients is necessary. When pregnancy is used only in case of emergency.

Storage conditions of the drug Konyne 80

At a temperature of 2-8 ° C (do not freeze). During transportation the concentrate of the preparation can be stored for up to 1 month at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf life of Konyne 80

2 years.

Do not use after the expiry date printed on the package.